Zhejiang Jiuzhou Pharmaceutical Co., Ltd

SHSE:603456 Stock Report

Market Cap: CN¥10.7b

Zhejiang Jiuzhou Pharmaceutical Future Growth

Future criteria checks 1/6

Zhejiang Jiuzhou Pharmaceutical is forecast to grow earnings and revenue by 14.5% and 4.8% per annum respectively. EPS is expected to grow by 18.4% per annum. Return on equity is forecast to be 9.7% in 3 years.

Key information

14.5%

Earnings growth rate

18.42%

EPS growth rate

Pharmaceuticals earnings growth18.3%
Revenue growth rate4.8%
Future return on equity9.75%
Analyst coverage

Low

Last updated20 May 2026

Recent future growth updates

Analysis Article • Apr 11

Zhejiang Jiuzhou Pharmaceutical Co., Ltd Just Missed Revenue By 17%: Here's What Analysts Think Will Happen Next

As you might know, Zhejiang Jiuzhou Pharmaceutical Co., Ltd ( SHSE:603456 ) last week released its latest full-year...

Recent updates

Analysis Article • Feb 08

Zhejiang Jiuzhou Pharmaceutical (SHSE:603456) Seems To Use Debt Quite Sensibly

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Analysis Article • Dec 31

Investors Holding Back On Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456)

Zhejiang Jiuzhou Pharmaceutical Co., Ltd's ( SHSE:603456 ) price-to-earnings (or "P/E") ratio of 17.6x might make it...
Analysis Article • Oct 01

Zhejiang Jiuzhou Pharmaceutical Co., Ltd's (SHSE:603456) Shares Leap 25% Yet They're Still Not Telling The Full Story

Zhejiang Jiuzhou Pharmaceutical Co., Ltd ( SHSE:603456 ) shareholders would be excited to see that the share price has...
Analysis Article • Sep 25

Zhejiang Jiuzhou Pharmaceutical (SHSE:603456) Seems To Use Debt Quite Sensibly

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Jun 13

Here's Why Zhejiang Jiuzhou Pharmaceutical (SHSE:603456) Can Manage Its Debt Responsibly

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Analysis Article • May 24

Zhejiang Jiuzhou Pharmaceutical Co., Ltd's (SHSE:603456) Business And Shares Still Trailing The Market

With a price-to-earnings (or "P/E") ratio of 13.8x Zhejiang Jiuzhou Pharmaceutical Co., Ltd ( SHSE:603456 ) may be...
Analysis Article • May 01

Zhejiang Jiuzhou Pharmaceutical's (SHSE:603456) Solid Earnings May Rest On Weak Foundations

Following the solid earnings report from Zhejiang Jiuzhou Pharmaceutical Co., Ltd ( SHSE:603456 ), the market responded...
Analysis Article • Apr 11

Zhejiang Jiuzhou Pharmaceutical Co., Ltd Just Missed Revenue By 17%: Here's What Analysts Think Will Happen Next

As you might know, Zhejiang Jiuzhou Pharmaceutical Co., Ltd ( SHSE:603456 ) last week released its latest full-year...
Analysis Article • Feb 28

Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) Shares Could Be 32% Above Their Intrinsic Value Estimate

Key Insights Using the Dividend Discount Model, Zhejiang Jiuzhou Pharmaceutical fair value estimate is CN¥15.81 Current...

Earnings and Revenue Growth Forecasts

SHSE:603456 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20285,858953N/A1,4621
12/31/20275,832984N/A1,3213
12/31/20265,553929N/A1,7493
3/31/20265,2196521,0401,675N/A
12/31/20255,5097301,1641,824N/A
9/30/20255,3567231,1001,680N/A
6/30/20255,2676578211,517N/A
3/31/20255,1756205811,414N/A
12/31/20245,161606103992N/A
9/30/20244,912697-192869N/A
6/30/20245,033886-43961N/A
3/31/20245,248989-185767N/A
12/31/20235,5231,0334311,360N/A
9/30/20235,6491,1453111,135N/A
6/30/20235,7451,0755241,386N/A
3/31/20235,8239945181,300N/A
12/31/20225,4459215121,226N/A
9/30/20225,4329047871,490N/A
6/30/20225,1508274501,098N/A
3/31/20224,5817474481,050N/A
12/31/20214,06363498678N/A
9/30/20213,906614-71456N/A
6/30/20213,507526115494N/A
3/31/20213,112443-59330N/A
12/31/20202,64738185400N/A
9/30/20202,404341308612N/A
6/30/20202,16726511357N/A
3/31/20202,010227206529N/A
12/31/20192,017238N/A554N/A
9/30/20191,952198N/A357N/A
6/30/20191,800171N/A406N/A
3/31/20191,785149N/A363N/A
12/31/20181,862157N/A265N/A
9/30/20181,752128N/A325N/A
6/30/20181,839163N/A282N/A
3/31/20181,798157N/A215N/A
12/31/20171,717148N/A275N/A
9/30/20171,696139N/A157N/A
6/30/20171,694147N/A177N/A
3/31/20171,697116N/A85N/A
12/31/20161,653111N/A137N/A
9/30/20161,559118N/A83N/A
6/30/20161,500126N/A44N/A
3/31/20161,458197N/A73N/A
12/31/20151,445200N/A141N/A
9/30/20151,432195N/A110N/A
6/30/20151,349170N/A98N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 603456's forecast earnings growth (14.5% per year) is above the savings rate (2.4%).

Earnings vs Market: 603456's earnings (14.5% per year) are forecast to grow slower than the CN market (26.8% per year).

High Growth Earnings: 603456's earnings are forecast to grow, but not significantly.

Revenue vs Market: 603456's revenue (4.8% per year) is forecast to grow slower than the CN market (16.3% per year).

High Growth Revenue: 603456's revenue (4.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 603456's Return on Equity is forecast to be low in 3 years time (9.7%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/12 08:36
End of Day Share Price 2026/06/12 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Zhejiang Jiuzhou Pharmaceutical Co., Ltd is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wanhua WuChina International Capital Corporation Limited
Zhu ChenCitic Securities Co., Ltd.
Mingrui WangEverbright Securities Co. Ltd.